ESR1 and breast carcinoma: Based on the immunohistochemical analysis, triple-negative breast cancers (TNBCs) have been identified as breast cancers that do not express oestrogen receptorα (ERα), progesterone receptor (PR) and Her-2 (triple-negative immunophenotype) [18].